Track Cidara Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cidara Therapeutics, Inc. CDTX · Stock Open Cidara Therapeutics, Inc. in new tab

221.38 USD
EPS
-26.68
P/B
5.42
ROE
-299.58
Beta
1.19
Target Price
62.00 USD
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Cidara Therapeutics reported strong progress in Q3 2025, marked by the early initiation of its Phase III ANCHOR trial for CD388 and receipt of Breakthrough Therapy Designation from the FDA.

  • CD388 has entered Phase III development, expanding the potential patient population from 50 million to over 100 million in the U.S. by including healthy adults over 65.
  • The ongoing ANCHOR trial, now over 50% enrolled, aims for completion in the Northern Hemisphere by December, leveraging a targeted participant group at high risk for influenza complications.
  • Cidara secured a $45 million milestone payment from Johnson & Johnson for the trial initiation and was awarded $339 million from BARDA for expanded manufacturing and clinical development.
  • CD388 has received Breakthrough Therapy Designation, promising expedited regulatory pathways and enhanced FDA guidance.
  • The Phase IIb NAVIGATE study demonstrated a 76.1% protective efficacy against influenza, underpinning the drug's differentiated profile and bolstering confidence for Phase III success.
📅
Loading chart...
Key Metrics
EPS-26.68
Book Value11.61
Price to Book5.42
Debt/Equity1.89
% Insiders1.118%
Growth
Revenue Growth-0.94%
Estimates
Forward P/E-8.05
Forward EPS-7.81
Target Mean Price62.00

DCF valuation

Model fair value for Cidara Therapeutics, Inc. (CDTX)
Result
Sign in to run the valuation for CDTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 62.00 USD (low 53.00, high 75.00)
Low 53.00
Mean 62.00
High 75.00
Price 221.38
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cidara Therapeutics, Inc. Logo Cidara Therapeutics, Inc. Analysis (CDTX)

United States Health Care Official Website Stock

Is Cidara Therapeutics, Inc. a good investment? Cidara Therapeutics, Inc. (CDTX) is currently trading at 221.38 USD. Market analysts have a consensus price target of 62.00 USD. This suggests the asset is currently trading above analyst expectations.

Investor FAQ

Does Cidara Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cidara Therapeutics, Inc.?

Cidara Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Exchange Ticker
NGM (Sweden) CDTX
FRA (Germany) 20D.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 24, 2024 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion